Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
Mikhail Kosiborod, MD
Stephen J. Greene, MD, FACC, FHFSA
AHA 2024 and Acoramidis: Impact on the Future of ATTR-CM Patient Care
Mazen Hanna, MD
LDL-C Management Trends in ASCVD Patients
Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
John Russell, MD
Noel Dasgupta, MD, FACC
Sami Khella, MD
Bempedoic acid reduces adverse limb events in patients with PAD
Marc Bonaca, MD
No benefit of routine spironolactone post-MI
Sanjit Jolly, MD
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Promising results with oral Lp(a) inhibitor in phase 2 trial
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Subodh Verma, MD, PhD
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
Shawna Nesbitt, MD
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Chisato Izumi, MD, PhD
Acoramidis reduces all-cause mortality in ATTR-CM
Daniel Judge, MD
Effect of decision support system on early optimization of lipid-lowering therapy
Kausik Ray, MBChB, MD, MPhil
Tirzepatide reduces HF events in patients with HFpEF and obesity
Milton Packer, MD
Audit and feedback strategy for pharmacists improves HF care
Alexander Sandhu, MD
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
Léna Rivard, MD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.